Literature DB >> 15828026

Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development.

Elisabetta Melloni1, Paola Secchiero, Claudio Celeghini, Diana Campioni, Vittorio Grill, Lia Guidotti, Giorgio Zauli.   

Abstract

The expression and function of surface TRAIL and TRAIL receptors were investigated in primary megakaryocytic cells, generated in serum-free liquid phase from peripheral human CD34(+) cells. The surface expression of both TRAIL and "death receptor" TRAIL-R2 became detectable starting from the early phase of megakaryocytic differentiation (day 6 of culture) and persisted at later (days10-14) culture times. On the other hand, "death receptor" TRAIL-R1, "decoy receptors" TRAIL-R3, and TRAIL-R4 were barely detectable or undetectable at any time point examined. Addition of recombinant TRAIL at day 6 of culture increased the rate of spontaneous apoptosis of CD34(+)/CD41(dim) megakaryoblasts and it significantly decreased the total output of mature megakaryocytic cells evaluated after additional 4-8 days of culture. Conversely, addition in culture of TRAIL-R2-Fc chimera, which blocked the interaction between endogenous TRAIL and TRAIL-R2 on the surface of cultured megakaryocytic cells, increased the total megakaryocytic cell count. In addition, recombinant TRAIL promoted a small but reproducible increase of maturation in the surviving megakaryocytic cell population, evaluated by both phenotypic analysis and morphology. A similar pro-maturation effect was observed when TRAIL was added to bone marrow-derived CD61(+) megakaryocytic cells. Thus, our data suggest a role of TRAIL as a regulator of megakaryocytopoiesis. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15828026     DOI: 10.1002/jcp.20358

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.

Authors:  Muna Iraqi; Jose Perdomo; Feng Yan; Philip Y-I Choi; Beng H Chong
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 2.  Non-apoptotic functions of caspases in myeloid cell differentiation.

Authors:  Stéphanie Solier; Michaela Fontenay; William Vainchenker; Nathalie Droin; Eric Solary
Journal:  Cell Death Differ       Date:  2017-02-17       Impact factor: 15.828

3.  Proposed megakaryocytic regulon of p53: the genes engaged to control cell cycle and apoptosis during megakaryocytic differentiation.

Authors:  Pani A Apostolidis; Stephan Lindsey; William M Miller; Eleftherios T Papoutsakis
Journal:  Physiol Genomics       Date:  2012-05-01       Impact factor: 3.107

Review 4.  Apoptosis: role in myeloid cell development.

Authors:  Shilpa Sarvothaman; Ram Babu Undi; Satya Ratan Pasupuleti; Usha Gutti; Ravi Kumar Gutti
Journal:  Blood Res       Date:  2015-06-25

Review 5.  Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra.

Authors:  Ammad Ahmad Farooqi; Cosmo Damiano Gadaleta; Girolamo Ranieri; Sundas Fayyaz; Ilaria Marech
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

6.  Apoptotic mediators in patients with severe and non-severe dengue from Brazil.

Authors:  Daniel Limonta; Amanda Torrentes-Carvalho; Cíntia Ferreira Marinho; Elzinandes Leal de Azeredo; Luiz José de Souza; Ana Rita C Motta-Castro; Rivaldo Venâncio da Cunha; Claire Fernandes Kubelka; Rita Maria Ribeiro Nogueira; Luzia Maria de-Oliveira-Pinto
Journal:  J Med Virol       Date:  2013-10-29       Impact factor: 2.327

7.  Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.

Authors:  Tatsushi Yoshida; Kenta Yamasaki; Kenjiro Tadagaki; Yasumichi Kuwahara; Akifumi Matsumoto; Adèm Ejub Sofovic; Noriko Kondo; Toshiyuki Sakai; Tsukasa Okuda
Journal:  Int J Oncol       Date:  2021-12-27       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.